International Journal of Health Sciences and Engineering (IJHSE)
Website: https://ijhse.com
ISSN: 3049-3811
Vol. 1, Issue 1, January-June, 2025
Page No.: 01-08

Review

Mesalamine Microemulsions for Crohn's Disease: A Review

Subham Mandal, Suraj Mandal*
Department of Pharmacy, IIMT College of Medical Sciences, IIMT University, O-Pocket, Ganganagar, Meerut, 250001, U.P., India

Corresponding Author:
Suraj Mandal

Email:
sk8006721807@gmail.com

Conflict of interest: *NIL*

Article History
Received: 03/01/2025
Accepted: 22/01/2025
Published: 10/02/2025

Abstract: *This analysis delves into the promise of mesalamine-encapsulated microemulsions in improving bioavailability and therapeutic effectiveness for Crohn's disease. Crohn's disease, a persistent inflammatory condition of the bowel, frequently necessitates precise medication administration owing to the particular sites of inflammation found in the gastrointestinal system. Mesalamine, a commonly utilised treatment, exhibits restricted efficacy owing to its inadequate absorption in the upper gastrointestinal tract and swift metabolic breakdown. This manuscript explores the obstacles linked to conventional mesalamine formulations and investigates the latest innovations in microemulsion-driven delivery mechanisms aimed at enhancing drug solubility, stability, and precise targeting. Innovative microemulsion methodologies, such as pH-sensitive and enzyme-responsive frameworks, exhibit potential in overcoming the shortcomings of current therapies, creating opportunities for more efficient and patient-centric treatment alternatives.*

Keywords: *Crohn's Disease, Mesalamine, Microemulsions, Bioavailability, Targeted Drug Delivery, pH-sensitive Systems, Controlled Release*

Introduction on Crohn's Disease

Crohn's disease (CD) is a subtype of inflammatory bowel disease (IBD) that primarily affects the gastrointestinal tract. The incidence of CD is rising, particularly in industrialized nations, possibly due to environmental and lifestyle factors that influence gut health[1]. CD presents unique challenges due to its chronic, relapsing nature and its potential to affect any part of the GI tract, though it often targets the ileum and colon.

The intricate origins of CD encompass hereditary factors, immune system imbalances, and external environmental impacts. Genetic elements, including NOD2 variations, may interfere with immune reactions and make individuals more susceptible to Crohn's disease[2]. The influence of environmental elements such as dietary habits and the makeup of the microbiome plays a significant role in the advancement of diseases. Complications associated with Crohn's disease are prevalent, encompassing fistulas, strictures, abscesses, and a heightened likelihood of colorectal cancer, all of which highlight the necessity for efficient, focused treatment options[3].

Importance of Mesalamine

Mesalamine, referred to as 5-aminosalicylic acid (5-ASA), has established itself as a fundamental element in the treatment of mild to moderate Crohn's disease. The therapeutic effect mainly focusses on suppressing pro-inflammatory cytokines, including interleukin-1 (IL-1) and tumour necrosis factor-alpha (TNF-α), which consequently diminishes inflammation in the gastrointestinal tract[4]. In contrast to corticosteroids and immunosuppressants, mesalamine exhibits a reduced incidence of side effects, rendering it a more appropriate option for prolonged utilisation[5]. Nonetheless, attaining optimal levels of mesalamine at sites of inflammation proves to be difficult because of the drug's pharmacokinetic properties, leading to diminished bioavailability.

Challenges in Mesalamine Bioavailability

The therapeutic constraints of mesalamine arise from its limited permeability within the intestinal barrier and its swift metabolism occurring in the upper gastrointestinal tract. As a result, the oral route of drug delivery frequently does not achieve sufficient concentrations in the distal intestines, which is usually where inflammation is most pronounced in patients with Crohn's disease[6]. Moreover, the absorption characteristics of mesalamine require sophisticated drug delivery mechanisms to improve stability, boost absorption, and facilitate targeted release, thereby maximising therapeutic effectiveness in the distal gastrointestinal tract[7].

2. Current Mesalamine Formulations and Their Limitations

To address mesalamine's low bioavailability, various formulations have been developed.

However, each has inherent limitations that hinder effective treatment of CD.

Oral Formulations

Oral mesalamine formulations are convenient for patients and are widely used; however, they encounter substantial challenges. Mesalamine is poorly absorbed in the upper GI tract, which significantly limits its efficacy in the distal intestines where Crohn's-related inflammation is often more severe[8]. Consequently, high doses are frequently required to achieve therapeutic concentrations, leading to potential side effects and increased systemic exposure, which limits its practicality for long-term use.

Rectal Formulations

Rectal formulations, including suppositories and enemas, are effective for localized delivery to the colon. While rectal mesalamine can reduce inflammation in the colon, it is impractical for treating inflammation located higher in the GI tract, such as in the ileum or small intestine. Additionally, patient discomfort associated with rectal administration limits its acceptability and adherence[9].

Modified-Release Formulations

Modified-release formulations, which include extended-release and pH-sensitive versions, aim to address the absorption and localization issues associated with standard mesalamine delivery. Extended-release mesalamine aims to maintain therapeutic concentrations over a longer duration, while pH-sensitive coatings are designed to release the drug in response to the acidic environment of the distal GI tract. However, these formulations still encounter inconsistencies, as the pH and transit times vary across the intestines, leading to variable therapeutic outcomes[10].

3. Microemulsion Systems for Drug Delivery

Microemulsion systems have emerged as a promising solution to enhance mesalamine's bioavailability, stability, and targeting within the GI tract. Microemulsions are typically composed of oil, water, and surfactants, which stabilize drug encapsulation and can be tailored to respond to specific GI conditions.

Types of Microemulsions

- **Oil-in-Water (O/W) Microemulsions**: These formulations are well-suited for hydrophobic drugs like mesalamine, as they improve solubility and bioavailability within the GI tract[11].
- **Water-in-Oil (W/O) Microemulsions**: While typically used for topical applications, W/O microemulsions face challenges in oral administration due to stability issues in aqueous environments, limiting their applicability for CD[12].
- **Bicontinuous Microemulsions**: These systems, where both oil and water phases are interconnected, allow for versatile drug solubility and have shown potential for incorporating both hydrophilic and lipophilic drugs. Bicontinuous microemulsions offer flexibility in targeting various regions within the GI tract affected by Crohn's disease[13].

Advantages of Microemulsions for Crohn's Disease

Microemulsion-based systems offer unique benefits for treating CD. They enhance mesalamine solubility, improve its bioavailability, and enable controlled, targeted release. Some microemulsions are designed to respond to pH or enzyme triggers, ensuring mesalamine release specifically within inflamed regions of the distal intestines, which is crucial for effective therapy in Crohn's disease[14]. This targeted approach reduces systemic exposure and minimizes potential side effects, offering a more patient-friendly treatment option.

Responsive Formulations

Innovative approaches within microemulsion systems have focused on adaptive delivery mechanisms, such as pH-sensitive and enzyme-responsive technologies. By using polymers like Eudragit S100, mesalamine can be designed to release specifically in response to the pH levels found in the distal intestine, where inflammation is common in CD patients. Enzyme-responsive formulations, meanwhile, target specific enzymatic environments found in inflamed tissue, releasing mesalamine where it is most needed and reducing unnecessary systemic absorption[15].

3. Microemulsion Systems for Drug Delivery

Microemulsions are emerging as a promising delivery system for mesalamine, addressing limitations in solubility, bioavailability, and targeted release within the gastrointestinal (GI) tract. These systems are composed of oil, water, and surfactants, forming a stable, isotropic mixture that can be tailored for specific drug delivery needs. The small droplet size and high surface area of microemulsions enhance drug absorption, making them suitable for oral administration, which is critical for managing Crohn's disease[16].

Types of Microemulsions

- **Oil-in-Water (O/W) Microemulsions**: O/W microemulsions consist of oil droplets dispersed in a continuous water phase, which makes them suitable for hydrophobic drugs like mesalamine. This configuration allows the drug to be more readily absorbed in the GI tract, enhancing its bioavailability and enabling it to reach distal intestinal regions where Crohn's disease inflammation is common. By increasing the solubility of mesalamine in aqueous environments, O/W microemulsions improve the therapeutic

effect of the drug while reducing the need for high doses.

- **Water-in-Oil (W/O) Microemulsions**: In W/O systems, water droplets are dispersed within an oil phase, which is advantageous for certain applications, such as topical drug delivery. However, W/O microemulsions face stability challenges in the aqueous GI environment, limiting their suitability for oral delivery. The water-based droplets are prone to breaking down in the acidic conditions of the stomach, making it difficult to maintain mesalamine's integrity until it reaches the target areas in the intestines[17]. As a result, these microemulsions are less practical for treating CD via oral administration.
- **Bicontinuous Microemulsions**: Bicontinuous microemulsions are characterized by interconnected oil and water phases, allowing both hydrophilic and lipophilic drugs to dissolve effectively. This structure offers versatility in delivering drugs with diverse solubility profiles, making it particularly useful for Crohn's disease where treatment may benefit from both local anti-inflammatory agents and supportive therapies. Bicontinuous microemulsions provide an adaptable platform for delivering mesalamine alongside adjunct therapies, which could lead to enhanced treatment outcomes[18].

Advantages of Microemulsions in Crohn's Disease

Microemulsion systems bring specific advantages to CD treatment, including:

- **Enhanced Solubility and Bioavailability**: Mesalamine is poorly soluble in water, which reduces its effectiveness in the GI tract. Microemulsions improve the solubility of mesalamine, allowing higher concentrations of the drug to be absorbed. This enhanced solubility directly translates into increased bioavailability, ensuring that therapeutic doses reach inflamed sites in the distal intestines, thus improving treatment efficacy[19].
- **Controlled, Targeted Release**: Microemulsions can be engineered to respond to specific GI tract conditions, such as pH or enzyme presence. In Crohn's disease, inflammation often occurs in areas with altered pH or elevated enzyme activity, particularly in the distal intestine. pH-sensitive or enzyme-responsive microemulsions are designed to release mesalamine precisely in these inflamed regions, providing targeted relief while reducing systemic side effects[20]. This targeted release approach enhances patient compliance by lowering the frequency of adverse effects and potentially reducing dosing frequency.
- **Improved Stability and Drug Protection**: Microemulsions offer a stable environment that protects mesalamine from premature degradation, particularly in the acidic conditions of the stomach. This protection allows the drug to maintain its efficacy as it travels through the GI tract, ultimately releasing in the targeted areas where it can exert its anti-inflammatory effects. Stability is critical for achieving consistent therapeutic outcomes in Crohn's disease, where variable GI conditions can affect drug release and efficacy.

4. Mechanisms of Mesalamine in Inflammation Management

Mesalamine is known for its multifaceted role in managing inflammation, making it an effective treatment for Crohn's disease. Its mechanisms include the inhibition of pro-inflammatory pathways, antioxidant activity, and modulation of the gut microbiota—all of which contribute to reducing inflammation and promoting long-term remission in Crohn's disease patients.

Inhibition of Cytokines and Leukotriene Pathways

Mesalamine's primary anti-inflammatory effect stems from its ability to inhibit the production and activity of pro-inflammatory cytokines, such as interleukin-1 (IL-1) and tumor necrosis factor-alpha (TNF-α). These cytokines are critical mediators in the inflammatory response that characterizes Crohn's disease. By reducing IL-1 and TNF-α levels, mesalamine effectively dampens the immune response within the GI tract, preventing the excessive inflammation that leads to tissue damage and symptom exacerbation in CD[21]. Additionally, mesalamine impacts leukotriene pathways, which are involved in inflammatory signaling and play a role in CD's pathophysiology. By inhibiting leukotrienes, mesalamine contributes to a reduction in inflammation, providing symptomatic relief.

Antioxidant Properties and ROS Scavenging

Crohn's disease is associated with increased oxidative stress in the GI tract, as reactive oxygen species (ROS) accumulate and damage tissues. Mesalamine has antioxidant properties that help neutralize these ROS, protecting the mucosal lining from oxidative[22]. The reduction in ROS prevents further tissue injury, alleviates inflammation, and supports mucosal healing—an essential factor for achieving and maintaining remission in Crohn's disease. This antioxidant effect also contributes to the long-term therapeutic benefit of mesalamine, as it limits the progression of inflammation and the

development of complications associated with chronic oxidative stress in the intestines.

Modulation of Gut Microbiota and Mucin Production

Recent research suggests that mesalamine influences the composition of the gut microbiota, promoting the growth of beneficial bacteria while suppressing pathogenic strains. This modulation is significant because an imbalanced microbiota, or dysbiosis, is often implicated in Crohn's disease, where it exacerbates inflammation and compromises gut health. By promoting a healthier microbiota, mesalamine indirectly supports immune balance and reduces inflammation[23].

In addition to microbiota modulation, mesalamine enhances the production of mucin, a glycoprotein that forms a protective barrier on the intestinal lining. This mucosal barrier serves as a defense against pathogenic bacteria and prevents translocation of harmful microbes into the intestinal tissues. By strengthening the mucosal barrier, mesalamine reduces bacterial invasion and inflammation, contributing to sustained remission and better long-term outcomes for CD patients. This combined effect on the microbiota and mucosal barrier highlights mesalamine's role not only in acute inflammation reduction but also in maintaining intestinal health over time.

5. Formulation Development of Mesalamine Microemulsions

The development of mesalamine microemulsions for Crohn's disease treatment focuses on enhancing the drug's stability, bioavailability, and targeted delivery. Microemulsions are typically composed of oil, water, and surfactants in carefully balanced ratios, which facilitate drug encapsulation and provide a stable delivery environment. Formulation challenges include selecting appropriate components and ensuring the microemulsion remains stable under varying gastrointestinal (GI) conditions. Additionally, microemulsions can be modified with pH-sensitive and enzyme-responsive polymers to enable targeted release, aligning drug delivery with the specific needs of Crohn's disease patients.

Composition and Stability Considerations

The foundation of a stable microemulsion involves selecting the optimal combination of oil, water, surfactants, and co-surfactants. These components must be balanced to create a stable, isotropic mixture that can encapsulate mesalamine effectively and ensure its release in the intended regions of the GI tract. The choice of surfactants and co-surfactants is critical, as they reduce surface tension, stabilize droplet formation, and ensure even dispersion of mesalamine within the microemulsion[24].

Surfactants such as Tween 80 or Span 80 are commonly used in mesalamine microemulsions due to their capacity to stabilize both hydrophilic and lipophilic components. Co-surfactants like propylene glycol can further enhance stability, preventing droplet coalescence and ensuring the microemulsion remains intact as it moves through the GI tract. Additionally, the oil phase can be adjusted based on the desired release profile and drug solubility needs; oils like medium-chain triglycerides (MCT) provide a stable environment for hydrophobic drugs and aid in controlled release. The specific ratio of these components influences not only stability but also drug encapsulation efficiency—a critical factor for achieving therapeutic concentrations of mesalamine at inflammation sites in the distal intestine. Optimizing these ratios allows for greater encapsulation and prevents premature release of mesalamine in the upper GI tract, where absorption is minimal, ensuring it reaches the targeted sites in active form[25].

Role of pH-Sensitive Polymers

In Crohn's disease treatment, a significant challenge is achieving precise drug release in the distal intestines, where inflammation is typically most severe. pH-sensitive polymers, such as Eudragit S100, are incorporated into microemulsion systems to address this challenge by facilitating drug release in response to specific pH levels. Eudragit S100, for instance, dissolves at a pH above 7, which aligns with the pH environment in the terminal ileum and colon, common sites of Crohn's disease inflammation[26]. This pH responsiveness allows mesalamine to remain stable in the acidic conditions of the stomach and upper intestine, preventing premature release and degradation.

The integration of pH-sensitive polymers into mesalamine microemulsions has shown promise in enhancing local drug availability. Studies report that pH-sensitive microemulsions improve drug retention in the distal GI regions, enabling higher therapeutic concentrations precisely where they are needed[27]. This approach reduces systemic absorption and associated side effects, offering a more localized and effective treatment for Crohn's disease.

Enzyme-Responsive Microemulsions

In addition to pH sensitivity, enzyme-responsive microemulsions are designed to release mesalamine upon exposure to specific enzymes prevalent in inflamed regions of the GI tract. Crohn's disease inflammation is associated with elevated levels of enzymes such as myeloperoxidase and proteases. By leveraging enzyme-responsive polymers, microemulsions can be engineered to release mesalamine selectively in inflamed tissues, where these enzymes are more abundant[28].

Enzyme-responsive formulations minimize systemic drug exposure by ensuring mesalamine is released only where inflammation is present. This targeted release is particularly beneficial for long-term CD management, as it reduces the frequency of

dosing required and lowers the risk of side effects. Enzyme-responsive microemulsions represent a promising avenue for delivering mesalamine in a more controlled and site-specific manner, thereby improving the efficacy and safety profile of Crohn's disease therapies.

6. In Vitro and In Vivo Efficacy Studies

The effectiveness of mesalamine microemulsions for Crohn's disease has been demonstrated through extensive in vitro and in vivo studies. These studies are essential for evaluating the stability, bioavailability, and anti-inflammatory effects of microemulsion systems, confirming their potential as a superior delivery method for mesalamine.

In Vitro Studies

In vitro studies are conducted to assess the stability, droplet size, encapsulation efficiency, and release profiles of mesalamine microemulsions under simulated gastrointestinal conditions. The droplet size of the microemulsion is a key factor influencing its stability and absorption. Studies have shown that microemulsions with smaller droplet sizes are more stable and have enhanced bioavailability due to increased surface area for absorption. Additionally, smaller droplets are better absorbed in the GI tract, allowing for more efficient drug delivery to the distal intestines.

Stability tests simulate the acidic environment of the stomach and the more neutral pH of the intestines, ensuring the microemulsion maintains integrity and only releases mesalamine at the target sites. Release profile studies assess how the microemulsion responds to changes in pH, confirming that pH-sensitive polymers like Eudragit S100 release mesalamine effectively in the distal intestine[30]. Furthermore, encapsulation efficiency tests measure the proportion of mesalamine successfully encapsulated within the microemulsion. High encapsulation efficiency is crucial for achieving therapeutic concentrations of the drug in Crohn's disease-affected areas.

In Vivo Animal Studies

Animal models of Crohn's disease are used to study the bioavailability, absorption rates, and anti-inflammatory effects of mesalamine microemulsions in vivo. These studies provide insight into how the microemulsion system performs under physiological conditions, giving a more accurate indication of its potential effectiveness in human patients. Research has shown that mesalamine microemulsions improve bioavailability compared to traditional formulations, allowing for more consistent and higher concentrations of the drug in the distal GI tract[31].

One study conducted on a rat model of Crohn's disease demonstrated that mesalamine microemulsions provided faster drug absorption and more sustained anti-inflammatory effects compared to conventional mesalamine tablets. The microemulsion formulation reduced inflammation markers, such as TNF-α and IL-1, in inflamed GI tissues, supporting its potential as an effective treatment for CD[32]. The study also noted fewer systemic side effects, as the targeted release minimized drug exposure outside the inflamed areas, highlighting the advantages of microemulsion systems in reducing adverse effects.

Another in vivo study investigated enzyme-responsive microemulsions and confirmed their ability to selectively release mesalamine in inflamed tissues with elevated enzyme levels. This study found that enzyme-responsive mesalamine microemulsions achieved better therapeutic outcomes in managing inflammation compared to non-responsive formulations, demonstrating the efficacy of this advanced delivery system for CD treatment[33].

7. Therapeutic Implications and Patient Outcomes

The therapeutic impact of mesalamine-loaded microemulsions on Crohn's disease (CD) management is significant, with direct implications for patient quality of life, healthcare cost savings, and treatment efficacy. By targeting inflammation more effectively within the gastrointestinal (GI) tract, these advanced delivery systems offer promising improvements in clinical outcomes.

Impact on Patient Quality of Life

One of the primary goals in CD treatment is to reduce the frequency and severity of inflammation, thereby alleviating symptoms such as abdominal pain, diarrhea, and fatigue. Traditional mesalamine formulations often face bioavailability and stability issues, limiting their efficacy. However, microemulsion systems, with their improved drug targeting and controlled release, can maintain therapeutic concentrations of mesalamine at inflamed sites in the distal intestines, offering more consistent symptom relief.

The benefits of effective inflammation control extend beyond physical relief. Patients who experience fewer and less severe flare-ups report improved physical and mental well-being. As inflammation decreases, daily activities become more manageable, which in turn reduces the psychological burden associated with CD. Additionally, by minimizing the need for corticosteroids and other immunosuppressive therapies, which often have adverse side effects, microemulsions contribute to a more favorable long-term treatment plan, supporting sustained remission and enhanced quality of life.

Economic and Healthcare Benefits

In addition to improving patient quality of life, targeted mesalamine delivery through microemulsions offers substantial economic benefits. Crohn's disease is associated with high healthcare costs due to the frequency of relapses,

hospitalizations, surgeries, and the need for ongoing medication. These costs place a significant burden on both patients and healthcare systems. By improving drug delivery and bioavailability, microemulsion systems help reduce the frequency of disease relapse, which may lead to fewer hospital visits and a decreased need for invasive interventions[34].

The enhanced efficacy of microemulsions in reducing inflammation also has the potential to lower long-term healthcare costs. Effective, targeted therapy may prevent or delay the need for surgeries, which are common in advanced stages of CD and are costly in terms of both resources and patient recovery. By contributing to a more stable course of treatment, microemulsions allow healthcare providers to allocate resources more efficiently, leading to broader economic benefits in healthcare resource allocation.

8. Future Directions and Innovations in Microemulsion-Based Delivery

The field of microemulsion-based drug delivery for Crohn's disease is rapidly evolving, with ongoing research focused on further optimizing drug targeting, enhancing treatment efficacy, and developing novel therapeutic strategies. Key areas of innovation include advances in pH-responsive and enzyme-sensitive formulations, as well as exploring multi-component microemulsions for combination therapies.

Advances in pH-Responsive and Enzyme-Sensitive Formulations

Current microemulsion systems rely heavily on pH-sensitive and enzyme-responsive mechanisms to achieve targeted drug release in the inflamed regions of the GI tract. These methods have shown promising results in preclinical studies, enabling mesalamine to release specifically in response to conditions associated with Crohn's disease, such as changes in pH levels or the presence of specific enzymes. By further refining these adaptive delivery mechanisms, researchers are working towards creating microemulsions that can more precisely match the unique GI environment of each patient[35].

Emerging technologies in pH-sensitive polymers, like Eudragit S100, and novel enzyme-responsive coatings are being studied to enhance the specificity and efficiency of mesalamine release. Such advancements hold promise for creating a more personalized treatment approach, allowing drug release to be fine-tuned based on individual patient conditions, which could result in even greater reductions in inflammation and improved therapeutic outcomes. Additionally, research is focusing on integrating multi-layered microemulsion systems that can respond to multiple triggers, making them versatile enough to adapt to the complex conditions present in the CD-affected GI tract.

Exploring Multi-Component Microemulsions

Another exciting direction in microemulsion-based therapy for Crohn's disease is the development of multi-component systems. By incorporating multiple therapeutic agents into a single microemulsion, researchers aim to create combination therapies that address various aspects of CD pathogenesis. For instance, combining mesalamine with probiotics or anti-inflammatory peptides within a single microemulsion could offer synergistic benefits, improving treatment outcomes and reducing relapse rates[36-38].

Multi-component microemulsions also offer the potential for reducing the overall pill burden on patients, as multiple medications could be administered in one formulation, simplifying treatment regimens and improving adherence. This approach aligns with the growing interest in personalized medicine and the need for treatments that address the multifaceted nature of Crohn's disease. As research progresses, these combination therapies could emerge as a key strategy in CD management, providing more comprehensive and effective treatment options.

9. Conclusion

Microemulsion-based mesalamine delivery systems represent a significant advancement in Crohn's disease treatment. By enhancing mesalamine's bioavailability, stability, and targeted release, these systems address many of the limitations associated with traditional formulations. Therapeutic outcomes are improved, leading to enhanced patient quality of life, reduced reliance on invasive treatments, and potential cost savings for healthcare systems. Furthermore, ongoing innovations, such as pH-responsive and enzyme-sensitive microemulsions and multi-component formulations, pave the way for even more effective, patient-centric therapies. As these systems continue to be refined and evaluated, they hold the potential to transform the treatment landscape for Crohn's disease, offering hope for long-term management and improved patient outcomes.

References:

1. Ahmed, S., Ali, M., Ahmed, A., & Ramzan, M. (2017). Development and characterization of aceclofenac-loaded microsponges for topical delivery. *Arabian Journal of Chemistry, 10*, S991–S999. https://doi.org/10.1016/j.arabjc.2013.12.019
2. Amidon, S., Brown, J. E., & Dave, V. S. (2015). Colon-targeted oral drug delivery systems: Design trends and approaches. *AAPS PharmSciTech, 16*(4), 731–741. https://doi.org/10.1208/s12249-015-0299-7
3. Belali, N., Wathoni, N., & Muchtaridi, M. (2019). Advances in orally targeted drug delivery to the colon. *Journal of Advanced Pharmaceutical Technology & Research,*

10(3), 100–106. https://doi.org/10.4103/japtr.JAPTR_195_19

4. Bhatia, M., & Saini, M. (2018). Formulation and evaluation of curcumin microsponges for oral and topical drug delivery. *Progress in Biomaterials, 7*(3), 239–248. https://doi.org/10.1007/s40204-018-0092-3
5. Caban, M., & Lewandowska, U. (2023). Encapsulation of polyphenolic compounds based on hemicelluloses to enhance treatment of inflammatory bowel diseases and colorectal cancer. *Molecules, 28*(10), 4189. https://doi.org/10.3390/molecules28104189
6. Chauhan, S., & Harwansh, R. K. (2024). Recent advances in nanocarrier systems for ulcerative colitis: A new era of targeted therapy and biomarker integration. *Journal of Drug Delivery Science and Technology, 93*, 105466. https://doi.org/10.1016/j.jddst.2023.105466
7. Chen, Z., Sun, X. H., & Zhou, R. (2018). Oral delivery of curcumin loaded for improved systemic bioavailability and colonic anti-inflammatory activity. *Colloids and Surfaces B: Biointerfaces, 167*, 356–364. https://doi.org/10.1016/j.colsurfb.2018.03.061
8. Cheng, J., Shah, Y. M., & Gonzalez, F. J. (2012). Pregnane X receptor as a target for treatment of inflammatory bowel disorders. *Trends in Pharmacological Sciences, 33*(6), 323–330. https://doi.org/10.1016/j.tips.2012.04.001
9. Danda, S., & Brahma Chandan, K. (2013). Colon-targeted drug delivery: A review on primary and novel approaches. *Journal of Global Trends in Pharmaceutical Sciences, 4*(4), 1179–1183.
10. Danese, S., Sans, M., & Fiocchi, C. (2004). Inflammatory bowel disease: The role of environmental factors. *Autoimmunity Reviews, 3*(5), 394–400. https://doi.org/10.1016/j.autrev.2004.04.005
11. Fan L, Zuo S, Tan H, Hu J, Cheng J, Wu Q, Nie SP. Preventive effects of pectin with various degrees of esterification on ulcerative colitis in mice. Food & Function. 2020.
12. Kang RK, Mishr N, Rai VK. Guar Gum Micro-particles for Targeted Co-delivery of Doxorubicin and Metformin HCL for Improved Specificity and Efficacy Against Colon Cancer: In Vitro and In Vivo Studies. AAPS PharmSciTech. 2020 Feb;21(2):1-1.
13. Kapoor D, Maheshwari R, Verma K, Sharma S, Ghode P, Tekade RK. Coating technologies in pharmaceutical product development. In Drug Delivery Systems 2020 Jan 1 (pp. 665-719). Academic Press.
14. Kawashima, Y., Niwa, T., Takeuchi, H., Hino, T., Itoh, Y., Furuyama, S., et al. (1991). Characterization of polymorphs of tranilast anhydrate and tranilast monohydrate when crystallized by two solvent change spherical crystallization techniques. *Journal of Pharmaceutical Sciences, 80*(5), 472–478. https://doi.org/10.1002/jps.2600800517
15. Kedia S, Ahuja V. Epidemiology of inflammatory bowel disease in India: the Great Shift East. Inflammatory intestinal diseases. 2017;2(2):102-15.
16. Kucharzik T, Asthana AK. Medical Management 2: Conventional. InInflammatory Bowel Disease Nursing Manual 2019 (pp. 81-90). Springer, Cham.
17. Kumari, A., Jain, A., Hurkat, P., Tiwari, A., & Jain, S. K. (2018). Eudragit S100 coated microsponges for colon targeting of prednisolone. *Drug Development and Industrial Pharmacy, 44*(6), 902–913. https://doi.org/10.1080/03639045.2017.1413457
18. Li, R., Wang, Y., & Xu, X. (2017). Azide-triggered colon-specific drug delivery based on nitroreductase-containing bacteria. *Journal of Controlled Release, 260*, 54–63. https://doi.org/10.1016/j.jconrel.2017.05.031
19. Managlia E, Katzman RB, Brown JB, Barrett TA. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflammatory bowel diseases. 2013 Jul 17;19(10):2051-60
20. Managlia E, Katzman RB, Brown JB, Barrett TA. Antioxidant properties of mesalamine in colitis inhibit phosphoinositide 3-kinase signaling in progenitor cells. Inflammatory bowel diseases. 2013 Jul 17;19(10):2051-60.
21. Mandal, S., Km Bhumika, B., Kumar, M., Hak, J., Vishvakarma, P., Sharma, U. K., et al. (2023). A novel approach on microsponges drug delivery system: Method of preparations, application, and its future prospective. *Indian Journal of Pharmaceutical Education and Research, 58*(1), 45–63. https://doi.org/10.5530/ijper.58.1.8
22. Nidhi, Dadwal A, Hallan SS, Sharma S, Mishra N. Development of enteric-coated microspheres of embelin for their beneficial pharmacological potential in ulcerative colitis. Artificial cells, nanomedicine, and biotechnology. 2017 Aug 18;45(6):1092-100
23. Noreen A, Akram J, Rasul I, Mansha A, Yaqoob N, Iqbal R, Tabasum S, Zuber M, Zia KM. Pectins functionalized biomaterials; a new viable approach for biomedical applications: A review. International journal

of biological macromolecules. 2017 Aug 1;101:254-72.

24. Özdemir, S., Üner, B., Baranauskaite, J., Sümer, E., Yıldırım, E., Yaba, A., et al. (2023). Design and characterization of dexamethasone-loaded microsponges for the management of ulcerative colitis. *European Journal of Pharmaceutics and Biopharmaceutics, 187*, 34–45. https://doi.org/10.1016/j.ejpb.2023.04.007
25. Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharmaceutical Journal. 2016 Jul 1;24(4):458-72
29. InUlcerative Colitis 2019 (pp. 93-104). Springer, Milano.
30. Rogler G. Chronic ulcerative colitis and colorectal cancer. Cancer letters. 2014 Apr 10;345(2):235-41.
31. Salunke, A., & Upmanyu, N. (2021). Formulation, development, and evaluation of budesonide oral nano-sponges using DOE approach: Evidence. *Advanced Pharmaceutical Bulletin, 11*(2), 286–294. https://doi.org/10.34172/apb.2021.032
32. Sen, S., Sharma, A., Kriplani, P., & Guarve, K. (2023). Microsponges: A neoteric approach for the effective management of osteoarthritis. *Current Rheumatology Reviews, 19*(4), 385–399. https://doi.org/10.2174/1573397118666230405155241
33. Shahdadi Sardo, H., Saremnejad, F., Bagheri, S., Akhgari, A., Afrasiabi Garekani, H., & Sadeghi, F. (2019). A review on 5-aminosalicylic acid colon-targeted oral drug delivery systems. *International Journal of Pharmaceutics, 558*, 367–379. https://doi.org/10.1016/j.ijpharm.2019.01.019
34. Sharma A, Kaur N, Sharma S, Sharma A, Rathore MS, Ajay K, Mishra N. Embelin-loaded guar gum microparticles for the management of ulcerative colitis. Journal of microencapsulation. 2018 Feb 17;35(2):181-91.
35. Singh MN, Hemant KS, Ram M, Shivakumar HG. Microencapsulation: A promising technique for controlled drug delivery. Research in pharmaceutical sciences. 2010 Jul;5(2):65.
36. Srivastava, R., Kumar, D., & Pathak, K. (2012). Colonic luminal surface retention of meloxicam microsponges delivered by erosion-based colon-targeted matrix tablet. *International Journal of Pharmaceutics, 427*(2), 153–162. https://doi.org/10.1016/j.ijpharm.2012.01.029
26. Rashid M, Kaur V, Hallan SS, Sharma S, Mishra N. Microparticles as controlled drug delivery carrier for the treatment of ulcerative colitis: A brief review. Saudi Pharmaceutical Journal. 2016 Jul 1;24(4):458-72.
27. Ray G. Long-term maintenance treatment of ulcerative colitis in eastern India: a 15-year follow-up. Tropical doctor. 2018 Jul;48(3):207-13.
28. Rizzello F, Salice M, Calabrese C, Mazza M, Calafiore A, Calandrini L, Hrustemovic HP, Campieri M, Gionchetti P. Medical Treatment of Ulcerative Colitis: Does Traditional Therapy Still Have a Role?.
37. Veer, S. U., Gadhve, M. V., & Khedkar, A. N. (2014). Microsponge: A drug delivery system. *International Journal of Pharmaceutical and Clinical Research, 6*(Suppl), 385–390.
38. Yang, L., Chu, J. S., & Fix, J. A. (2002). Colon-specific drug delivery: New approaches and evaluation. *International Journal of Pharmaceutics, 235*(1–2), 1–15. https://doi.org/10.1016/S0378-5173(01)00982-2
39. Zhang, S., Langer, R., & Traverso, G. (2017). Nanoparticulate drug delivery systems targeting inflammation for treatment of inflammatory bowel disease. *Nano Today, 16*, 82–96. https://doi.org/10.1016/j.nantod.2017.04.001

*****